Healwell AI Seeks Investor Momentum Amid Strategic Shift and Analyst Revisions

Healwell AI reports 427% revenue surge to $103.8M and first positive adjusted EBITDA of $2.3M in fiscal 2025, while completing its transition to a pure-play AI company.

Healwell AI Inc. is currently holding one-on-one meetings with investors at the 38th Annual ROTH Conference in Dana Point, California, aiming to build momentum. The company's presence at this event is strategic, intended to showcase its growth narrative to a wider investment audience following a year of significant financial and operational transformation.

Financial Performance: Record Revenue Amid Ongoing Losses

The healthcare artificial intelligence firm reported substantial growth for fiscal 2025. Revenue from continuing operations surged to approximately $103.8 million, representing a dramatic 427% increase from the $19.7 million recorded the previous year. A key milestone was achieved as Healwell AI posted its first-ever positive adjusted EBITDA of $2.3 million, a notable turnaround from an adjusted EBITDA loss of $14.2 million in fiscal 2024.

However, this revenue growth has not yet translated to bottom-line profitability under International Financial Reporting Standards (IFRS). The company registered a net loss from continuing operations of $39.1 million for the period.

Completing the Transition to a Pure-Play AI Company

A major strategic overhaul was finalized in the fourth quarter of 2025. Healwell AI divested several clinic assets, generating roughly $9.7 million in cash proceeds. This move completed its evolution into a dedicated AI and software platform business, shedding its previous clinical operations.

The company's proprietary DARWEN™ AI platform has gained academic credibility, with its technology now validated across 47 peer-reviewed publications. Healwell AI's capital portfolio also includes a strategic $2 million investment in a vehicle holding an interest in xAI, which is now part of the broader SpaceX ecosystem.

Market Analysts Adjust Valuation Models

On March 12, 2026, equity research firm Stifel maintained its "Buy" recommendation for Healwell AI shares but revised its price target downward. The new target was set at C$3.10, reduced from the previous C$3.80. In parallel, the analysts adjusted their fair value estimate for the company from C$3.45 to C$2.85.

This reassessment was driven by more moderate growth assumptions, though expectations for improved future margins were strengthened. Stifel's official price target remains above its internal fair value calculation.

Currently, the stock trades significantly below both the price target and the fair value estimate. On a year-to-date basis, the equity has lost approximately half of its value. The coming quarters will reveal whether the company's conference outreach and operational progress can restore investor confidence. A critical measure will be the demonstrable quality of revenue generated from its focused AI and SaaS business segments.